Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 100.
237. lappuse
... give this product to children who have a breathing prob- lem such as chronic bronchitis or who have glaucoma ... give to children under 6 years of age unless directed by a doctor . ” ( 3 ) For products containing dimenhy- drinate ...
... give this product to children who have a breathing prob- lem such as chronic bronchitis or who have glaucoma ... give to children under 6 years of age unless directed by a doctor . ” ( 3 ) For products containing dimenhy- drinate ...
243. lappuse
... give this product to chil- dren who have a breathing problem such as chronic bronchitis , or who have glaucoma , without first consulting the child's doctor . " ( ii ) For products brompheniramine chlorpheniramine containing maleate ...
... give this product to chil- dren who have a breathing problem such as chronic bronchitis , or who have glaucoma , without first consulting the child's doctor . " ( ii ) For products brompheniramine chlorpheniramine containing maleate ...
246. lappuse
... give this product for per- sistent or chronic cough such as occurs with asthma or if cough is accom- panied by excessive phlegm ( mucus ) unless directed by a doctor . " ( 4 ) Oral antitussives— ( i ) For products containing codeine ...
... give this product for per- sistent or chronic cough such as occurs with asthma or if cough is accom- panied by excessive phlegm ( mucus ) unless directed by a doctor . " ( 4 ) Oral antitussives— ( i ) For products containing codeine ...
251. lappuse
... give this product to a child who has heart disease , high blood pressure , thyroid disease , or diabetes unless directed by a doctor . " ( D ) " Drug interaction precaution . Do not give this product to a child who is taking a ...
... give this product to a child who has heart disease , high blood pressure , thyroid disease , or diabetes unless directed by a doctor . " ( D ) " Drug interaction precaution . Do not give this product to a child who is taking a ...
252. lappuse
... give to children under 12 years of age unless directed by a doctor . ( 2 ) For a 0.025 - percent aqueous solution . Children 6 to under 12 years of age ( with adult supervision ) : 1 or 2 drops or sprays in each nostril not more often ...
... give to children under 12 years of age unless directed by a doctor . ( 2 ) For a 0.025 - percent aqueous solution . Children 6 to under 12 years of age ( with adult supervision ) : 1 or 2 drops or sprays in each nostril not more often ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning